Shots: Cardinal Health signed an agreement to divest its Cordis medical device business to H&F for ~ $1B including liabilities and working capital accounts. The transaction is expected to close […]readmore
Tags : Sell
Shots: Agios to receive ~$1.8B upfront in cash & ~$200M as regulatory milestones for Vorasidenib along with 5% royalties on sales of Tibsovo in the US from transaction close through […]readmore
Shots: Boston Scientific signs an agreement with Stark International and SERB SAS to sell its BTG specialty pharma business for $800M in cash. The transaction is expected to close in […]readmore
Shots: Co-Diagnostics’ JV CoSara has received CDSCO’s clearance to manufacture and sell its Saragene COVID-19 2-gene multiplex RT-PCR test as an IVD, intended for the qualitative detection of the SARS-CoV-2 […]readmore
Shots: AstraZeneca to receive up to $181M up front and sales-contingent payments of up to $17M. Juisve to get exclusive commercialization rights for Arimidex (anastrozole) and Casodex (bicalutamide) in a […]readmore
Shots: Eli Lilly to receive $75M upfront & $300M on the completion of transaction. Eddingpharm to get exclusive rights for Lilly’s two antibiotics, Ceclor and Vancocin and a manufacturing facility […]readmore
Shots: Immunogen to receive $65M as total deal value and OMERS to get royalties on sales of Kadcyla In 2015, Immunogen & IRH collaborated for Kadcyla’s royalty for $200M, where […]readmore